Chronic Spontaneous Urticaria Combined Atopic Dermatitis/Other Atopic Comorbidities: Clinical Characteristics, Therapeutic Response to Omalizumab, and Drug Survival
Dermatitis® · 28.05.2026
DOI: 10.1177/17103568261455284 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermatitis®, online erschienen am 28.05.2026. Verfasst von Ruiguo Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Dermatology, The First Affiliated Hospital (Southwest Hospital) of Army Medical University, Chongqing, China. Die Arbeit nennt 40 Literaturangaben.
Abstract (Originalsprache)
Background
Atopic comorbidities are common in chronic spontaneous urticaria (CSU), yet their impact on clinical presentation and omalizumab response remains poorly defined.
Objective
To compare clinical profiles and omalizumab treatment outcomes in CSU patients with atopic dermatitis (AD) and other atopic comorbidities (OACs).
Methods
This single-center retrospective study included 381 CSU patients treated with ≥3 doses of omalizumab (300 mg/4 weeks) and followed ≥6 months (January 2023–March 2025). Based on the presence or history of atopic comorbidities, patients were stratified into 3 groups: CSU with AD (CSU-AD, n = 76), CSU with OACs (CSU-OACs, n = 93), and CSU with no atopic comorbidities (CSU-NA, n = 212). Clinical features, treatment response (efficacy, speed, and adverse events), and—among 12-month completers—dose reduction/discontinuation and drug survival rates were analyzed.
Results
Of all enrolled patients, 44.4% had comorbid allergic diseases. CSU-OACs patients had earlier onset ( P = 0.033) and higher angioedema prevalence ( P = 0.042); CSU-AD showed higher baseline UAS7 ( P = 0.031). Overall omalizumab response rates did not differ significantly among the 3 groups ( P = 0.115), but a significantly higher portion of faster-response speed was observed in CSU-OAC ( P = 0.019). Adverse events were significantly higher in CSU-OACs ( P = 0.004), especially injection-site reactions ( P = 0.033) and systemic effects (eg, headache and fatigue; P = 0.025). Drug survival was significantly higher in the CSU-OAC vs. CSU-NA group ( P = 0.007).
Conclusion
CSU-AD differs only in higher baseline activity, otherwise resembling CSU-NA in treatment response and drug survival. CSU-OACs exhibit not only distinct features such as earlier onset, higher angioedema risk, faster response, and higher drug survival but also more adverse events, indicating that CSU-OAC requires individualized management. Larger multicenter studies are needed to further define the impact of AD and OACs in CSU.
Autor:innen und Institutionen
- From the Department of Dermatology, The First Affiliated Hospital (Southwest Hospital) of Army Medical University, Chongqing, China.
ORCID-Profile: Qiquan Chen
Zitieren
APA
Li, R., Chen, A., Yang, X., Huang, X., Li, S., Mu, Z., Li, R., Song, Z., & Chen, Q. (2026). Chronic Spontaneous Urticaria Combined Atopic Dermatitis/Other Atopic Comorbidities: Clinical Characteristics, Therapeutic Response to Omalizumab, and Drug Survival. Dermatitis®. https://doi.org/10.1177/17103568261455284
Vancouver
Li R, Chen A, Yang X, Huang X, Li S, Mu Z, et al. Chronic Spontaneous Urticaria Combined Atopic Dermatitis/Other Atopic Comorbidities: Clinical Characteristics, Therapeutic Response to Omalizumab, and Drug Survival. Dermatitis®. 2026. doi:10.1177/17103568261455284
BibTeX
@article{Li2026,
author = {Li, Ruiguo and Chen, Anqi and Yang, Xianjie and Huang, Xuewei and Li, Shifei and Mu, Zhikun and Li, Ran and Song, Zhiqiang and Chen, Qiquan},
title = {Chronic Spontaneous Urticaria Combined Atopic Dermatitis/Other Atopic Comorbidities: Clinical Characteristics, Therapeutic Response to Omalizumab, and Drug Survival},
journal = {Dermatitis®},
year = {2026},
doi = {10.1177/17103568261455284}
}
EUVIMED